Plasma Cell-Free Human Papillomavirus Oncogene E6 and E7 DNA Predicts Outcome in Oropharyngeal Squamous Cell Carcinoma

• Published in: The Journal of molecular diagnostics : JMD Vol. 22; no. 11; pp. 1333 - 1343
• Main Authors: Reder, Henrike, Taferner, Victor F., Wittekindt, Claus, Bräuninger, Andreas, Speel, Ernst-Jan M., Gattenlöhner, Stefan, Wolf, Gregor, Klussmann, Jens P., Wuerdemann, Nora, Wagner, Steffen
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.11.2020
• Subjects: Aged; Aged, 80 and over; Alphapapillomavirus - metabolism; Biomarkers, Tumor - blood; Biomarkers, Tumor - genetics; Cell-Free Nucleic Acids - blood; Cell-Free Nucleic Acids - genetics; DNA, Viral - blood; DNA, Viral - genetics; Female; Follow-Up Studies; Head and Neck Neoplasms - blood; Head and Neck Neoplasms - complications; Humans; Male; Middle Aged; Neoplasm Recurrence, Local - blood; Neoplasm Recurrence, Local - complications; Oncogene Proteins, Viral - genetics; Papillomavirus E7 Proteins - genetics; Papillomavirus Infections - blood; Papillomavirus Infections - complications; Papillomavirus Infections - virology; Pilot Projects; Real-Time Polymerase Chain Reaction; Repressor Proteins - genetics; Squamous Cell Carcinoma of Head and Neck - blood; Squamous Cell Carcinoma of Head and Neck - complications
• ISSN: 1525-1578; 1943-7811
• DOI: 10.1016/j.jmoldx.2020.08.002

Persistent human papillomavirus (HPV) infection is associated with the development of oropharyngeal squamous cell carcinoma (OPSCC), and increasing incidences of OPSCC are reported. The generally favorable treatment outcome in patients with HPV-driven OPSCC has brought de-escalation of treatment into discussion. Nevertheless, 13% to 25% develop a relapse within two years after current standard treatment. New biomarkers are urgently required to monitor therapy response, tumor burden, and minimal residual disease during follow-up. This observational study examined 50 patients with OPSCC to investigate plasma cell-free (cf) HPV-DNA derived from tumor cells before therapy and during follow-up. Real-time quantitative PCR was applied to quantify the DNA concentration of HPV oncogenes E6 and E7. A total of 85.7% of pretreatment samples from patients with HPV-driven OPSCC (n = 28) were positive for at least one marker, and cfHPV-DNA concentration increased with tumor size. Virtually no signals were detected in HPV-negative OPSCC patients (n = 20; P ≤ 0.001). Patients without clinical evidence of recurrence had significantly reduced cfHPV-DNA concentrations after therapy (P ≤ 0.001). Conversely, cfHPV-DNA levels increased or remained above threshold in five patients who had residual disease or developed recurrence. In conclusion, plasma cfHPV-DNA detection correlates with the clinical course of disease in patients with HPV-driven OPSCC. Consequently, extensive clinical investigation should be considered if cfHPV-DNA is detected during follow-up of patients with HPV-driven OPSCC.